171 related articles for article (PubMed ID: 15608561)
1. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Foucher C; Rattier S; Flavell DM; Talmud PJ; Humphries SE; Kastelein JJ; Ayyobi A; Pimstone S; Frohlich J; Ansquer JC; Steiner G;
Pharmacogenetics; 2004 Dec; 14(12):823-9. PubMed ID: 15608561
[TBL] [Abstract][Full Text] [Related]
2. Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.
Brisson D; Ledoux K; Bossé Y; St-Pierre J; Julien P; Perron P; Hudson TJ; Vohl MC; Gaudet D
Pharmacogenetics; 2002 Jun; 12(4):313-20. PubMed ID: 12042669
[TBL] [Abstract][Full Text] [Related]
3. Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.
Irvin MR; Zhang Q; Kabagambe EK; Perry RT; Straka RJ; Tiwari HK; Borecki IB; Shimmin LC; Stuart C; Zhong Y; Hixson JE; Arnett DK
Pharmacogenet Genomics; 2012 May; 22(5):367-72. PubMed ID: 22336959
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
[TBL] [Abstract][Full Text] [Related]
5. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
Gouni-Berthold I; Giannakidou E; Faust M; Berthold HK; Krone W
Atherosclerosis; 2005 Dec; 183(2):336-41. PubMed ID: 16285997
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate and metabolic syndrome.
Kraja AT; Province MA; Straka RJ; Ordovas JM; Borecki IB; Arnett DK
Endocr Metab Immune Disord Drug Targets; 2010 Jun; 10(2):138-48. PubMed ID: 20406163
[TBL] [Abstract][Full Text] [Related]
7. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Lemieux I; Salomon H; Després JP
Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
[TBL] [Abstract][Full Text] [Related]
8.
Morieri ML; Shah HS; Sjaarda J; Lenzini PA; Campbell H; Motsinger-Reif AA; Gao H; Lovato L; Prudente S; Pandolfi A; Pezzolesi MG; Sigal RJ; Paré G; Marcovina SM; Rotroff DM; Patorno E; Mercuri L; Trischitta V; Chew EY; Kraft P; Buse JB; Wagner MJ; Cresci S; Gerstein HC; Ginsberg HN; Mychaleckyj JC; Doria A
Diabetes; 2020 Apr; 69(4):771-783. PubMed ID: 31974142
[TBL] [Abstract][Full Text] [Related]
9. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.
Brouillette C; Bossé Y; Pérusse L; Gaudet D; Vohl MC
J Hum Genet; 2004; 49(8):424-432. PubMed ID: 15249972
[TBL] [Abstract][Full Text] [Related]
10. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.
Cavallero E; Dachet C; Assadolahi F; Martin C; Navarro N; Ansquer JC; Corda C; Foucher C; Juhan-Vague I; Jacotot B
Atherosclerosis; 2003 Jan; 166(1):151-61. PubMed ID: 12482562
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia.
Guérin M; Bruckert E; Dolphin PJ; Turpin G; Chapman MJ
Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):763-72. PubMed ID: 8640404
[TBL] [Abstract][Full Text] [Related]
12. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians.
Shin MJ; Kanaya AM; Krauss RM
Atherosclerosis; 2008 Jun; 198(2):313-9. PubMed ID: 18061194
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
15. Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study.
Do HQ; Nazih H; Luc G; Arveiler D; Ferrières J; Evans A; Amouyel P; Cambien F; Ducimetière P; Bard JM
Metabolism; 2009 Mar; 58(3):283-9. PubMed ID: 19217440
[TBL] [Abstract][Full Text] [Related]
16. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
[TBL] [Abstract][Full Text] [Related]
17. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
Tan CE; Chew LS; Tai ES; Chio LF; Lim HS; Loh LM; Shepherd J
Atherosclerosis; 2001 Feb; 154(2):469-74. PubMed ID: 11166781
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
19. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
